Our response to the revision of the EU General Pharmaceuticals Legislation Roadmap
Lilly wishes to offer this solution-oriented reply for improving the EU medicines ecosystem, making life better for patients, and facilitating the EU’s leadership in life sciences.
Our response to the EU Pharmaceutical Strategy Roadmap
Lilly welcomes the opportunity to respond to the European Commission’s Roadmap to the Pharmaceutical Strategy. Lilly pushes the boundaries of science to make conditions that are incurable today, treatable tomorrow. Our recommendations cut across four areas to make life better for patients and support the EU in being a world leader in life sciences. They also reflect learnings to date from COVID-19.
A strong EU-US relationship for patients
With today’s health challenges accentuated by the coronavirus pandemic, there’s no greater need for common action. Now is the time to push the EU-US relationship to the next level.